Alto Neuroscience to Present Late-Stage Clinical Data and Robust Platform at Upcoming Conferences

Alto Neuroscience, Inc., based in Los Altos, California, has announced a series of upcoming data presentations that will showcase the company's advancements in precision psychiatry and biomarker-based analyses. These presentations will be featured at the Society of Biological Psychiatry (SOBP) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings, scheduled to take place from May 9-11 in Austin, TX, and May 28-31 in Miami Beach, FL, respectively.

Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience, emphasized the significance of the data generated by the company to contribute to the scientific community and to develop new treatments for patients suffering from depression and schizophrenia. Etkin highlighted the strength of Alto’s precision psychiatry platform, which is bolstered by each new dataset. The company has systematically identified and prospectively replicated neurobiological markers linked to cognitive impairment in schizophrenia, using rigorous data science to validate these findings. These validated markers, such as the theta response, are critical for designing proof-of-concept studies, including the planned ALTO-101 study.

Alto's data presentations span several of its clinical programs, including ALTO-100, ALTO-101, and ALTO-300:

ALTO-100:
- Phase 2a study data identify and replicate a memory-based cognitive marker predicting a greater antidepressant response to ALTO-100.
- Analysis of Phase 3 vortioxetine data shows that baseline cognitive performance does not moderate response, indicating vortioxetine does not provide additional benefits for patients with poor baseline cognitive performance.
- A large depression trial analysis reveals that poor memory predicts worse functional outcomes in depression, underscoring the urgent need for better treatment options.

ALTO-101:
- Data from a randomized, double-blind, placebo-controlled Phase 1 study in healthy volunteers demonstrate significant effects of ALTO-101 on electrophysiological measures pertinent to cognitive processing, such as theta response and information processing speed, which are relevant to cognitive impairment in schizophrenia.
- Analysis of the Bipolar and Schizophrenia Network for Intermediate Phenotypes (BSNIP) studies identifies and replicates theta response as an EEG marker best associated with schizophrenia diagnosis and cognitive impairment. The relationship between theta response and processing speed, an indicator of cognitive impairment in schizophrenia, was particularly noted.

ALTO-300:
- Phase 2a study data highlight the identification and replication of an EEG-based cognitive marker predicting a better response to ALTO-300.

These findings will be detailed across multiple sessions at the SOBP Annual Meeting from May 9-11, 2024. Topics include the identification and replication of cognitive biomarkers for antidepressant effects in major depression, the non-association of baseline cognition with depression outcomes using vortioxetine, and the pro-cognitive pharmacodynamic effects of ALTO-101.

At the ASCP Annual Meeting from May 28-31, 2024, presentations will cover the pro-cognitive pharmacodynamic effects of ALTO-101 from brain and behavioral outcomes in a Phase 1 study, the clinical trials ecosystem's precision neuroscience, and the prevalence and correlates of cognitive impairment in depression.

Alto Neuroscience's mission is to redefine psychiatry by leveraging neurobiology to develop personalized, effective treatments. Their Precision Psychiatry Platform™ analyzes brain biomarkers through EEG activity, neurocognitive assessments, wearable data, and other factors to identify patients likely to respond to their drug candidates. The company’s pipeline includes novel treatments for depression, PTSD, schizophrenia, and other mental health conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!